Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
As the pharmaceutical industry evolves, Generative AI (GenAI) is becoming a vital tool for optimizing operations, expediting regulatory processes and driving innovation. With rising regulatory demands and competitive pressures to accelerate drug development, biopharma companies are increasingly turning to collaborative AI platforms with built-in compliance and adaptability.
Biopharma companies now face a critical decision: build an in-house AI solution or invest in an external platform. This decision impacts more than technology—it also affects costs, time to market, compliance and scalability.
Generative AI in regulatory writing refers to the use of AI to automate the drafting, structuring, and validation of regulatory documents, improving efficiency, consistency, and compliance in life sciences workflows.
For most biopharma organizations, buying a proven AI solution is more effective than building in-house, as it reduces implementation time, ensures compliance, and provides scalable, continuously updated capabilities without requiring significant internal resources.
In life sciences regulatory affairs, these decisions are particularly critical, where document quality, traceability, and compliance directly impact submission success and approval timelines.
One of the most impactful applications of generative AI in biopharma is in regulatory writing, where speed and accuracy are paramount. Generative AI is transforming regulatory documentation by turning structured clinical data into compliant, submission-ready content with improved consistency and traceability. For example, AI can automatically generate patient narratives from structured clinical data, ensuring consistency across documents while reducing hours of manual writing. These documents are crucial for regulatory approval and GenAI’s ability to automate and maintain accuracy makes it an invaluable asset. However, the complexity and costs of building and maintaining in-house GenAI solutions are often underestimated.
Advanced AI capabilities, especially those comparable to industry leaders, require continuous investment and specialized knowledge. In biopharma, data governance and compliance add to these demands. Developing in-house solutions can be further complicated in regulated environments, where maintaining an up-to-date system requires ongoing resources.
Tim Martin, Executive VP of Product & Development at Yseop: “In biopharma, the ‘build vs. buy’ decision for AI is ultimately about focus—do you want to be an AI developer or an innovator in drug development? By partnering with a proven GenAI provider, companies can streamline regulatory processes, enhance scalability and drive innovation without the burden of maintaining complex infrastructure.”
In biopharma, choosing between custom in-house solutions and proven external platforms means balancing flexibility with rapid deployment and compliance. External solutions also offer future-proofing, keeping pace with AI advancements to reduce reinvestment needs. Here are a few things to consider when making your decision.
Generative AI is no longer just a concept for the future; it is actively reshaping biopharma operations today. For companies aiming to leverage this technology effectively, choosing the right AI partner is essential to truly reduce costs, accelerate time to market and maintain regulatory compliance. By adopting a scalable, compliant solution from a trusted provider, biopharma companies benefit not only cutting-edge tools but also the assurance that their technology evolves in step with industry advancements.
In a field where the primary mission is drug development and patient care, partnering with a dedicated AI software provider allows biopharma companies to focus on what they do best—delivering innovative therapies. Rather than undertaking the resource-intensive task of building AI solutions internally, companies can rely on a partner equipped with the expertise and infrastructure needed to address industry-specific challenges, streamline workflows and foster impactful innovation.
Working with an AI partner ensures that biopharma companies stay at the forefront of technological progress, empowering them to advance toward their goals with confidence.
Most biopharma companies benefit from buying AI solutions, as it reduces implementation time, ensures compliance, and avoids the complexity of building and maintaining internal systems.
Building AI in-house involves high costs, long implementation timelines, ongoing maintenance, and challenges related to compliance and data governance.
Generative AI is used to automate document drafting, ensure consistency across content, and generate submission-ready regulatory documents.
Compliance ensures that AI-generated content meets regulatory standards such as GCP and ICH guidelines, which is critical for submission approval.
External AI platforms like Yseop provide scalability, faster deployment, continuous updates, and built-in compliance, allowing companies to focus on core drug development activities.